Literature DB >> 1963598

Evidence of a role for NMDA receptors in pain perception.

P Klepstad1, A Maurset, E R Moberg, I Oye.   

Abstract

Both chiral forms of ketamine caused analgesia when administered in subanesthetic doses to human volunteers suffering acute, experimentally induced ischemic pain. S-Ketamine was 4 times more potent than R-ketamine as an analgesic agent in this model system. The relative order of analgesic potency of the two enantiomers was compared to their relative affinity for phencyclidine (PCP) binding sites (associated with the NMDA receptor-operated ion channel) and for sigma binding sites (which are not associated with the NMDA receptor complex). The relative analgesic potency of the enantiomers correlated positively with their relative affinity for PCP sites and negatively with their relative affinity for sigma sites. The results strongly indicate that PCP sites, but not sigma sites, are functional receptors mediating the analgesic effect of ketamine. This is consistent with the hypothesis that NMDA receptors are essential for pain perception in humans. Disturbances of other sensory modalities, in particular somatosensory perception, vision and hearing, were the main side-effects observed. These effects were qualitatively similar for both enantiomers and were closely associated with their analgesic action. The NMDA type of excitatory amino acid receptor thus appears to be widely involved in the processing of sensory afferent signals in the human brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963598     DOI: 10.1016/0014-2999(90)90379-k

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

1.  Peripheral N-methyl-d-aspartate receptors contribute to mechanical hypersensitivity in a rat model of inflammatory temporomandibular joint pain.

Authors:  J J Ivanusic; D Beaini; R J Hatch; V Staikopoulos; B J Sessle; E A Jennings
Journal:  Eur J Pain       Date:  2010-08-02       Impact factor: 3.931

2.  Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion.

Authors:  M Knobloch; C J Portier; O L Levionnois; R Theurillat; W Thormann; C Spadavecchia; M Mevissen
Journal:  Toxicol Appl Pharmacol       Date:  2006-07-03       Impact factor: 4.219

Review 3.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 4.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

5.  Microglial Ca(2+)-activated K(+) channels are possible molecular targets for the analgesic effects of S-ketamine on neuropathic pain.

Authors:  Yoshinori Hayashi; Kodai Kawaji; Li Sun; Xinwen Zhang; Kiyoshi Koyano; Takeshi Yokoyama; Shinichi Kohsaka; Kazuhide Inoue; Hiroshi Nakanishi
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 6.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

7.  Successful use of ketamine for intractable cancer pain.

Authors:  Dominique A Lossignol; Myriam Obiols-Portis; Jean-Jacques Body
Journal:  Support Care Cancer       Date:  2004-10-06       Impact factor: 3.603

Review 8.  Clinically important drug interactions with intravenous anaesthetics in older patients.

Authors:  Helge Eilers; Claus Niemann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits.

Authors:  Wulf Hevers; Stephen H Hadley; Hartmut Lüddens; Jahanshah Amin
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

Review 10.  Pain management: physiopathology, future research and endpoints.

Authors:  M Sosnowski
Journal:  Support Care Cancer       Date:  1993-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.